Previous 10 | Next 10 |
Nevro (NYSE:NVRO) is scheduled to announce Q4 earnings results on Wednesday, February 24th, after market close.The consensus EPS Estimate is -$0.35 (+20.5% Y/Y) and the consensus Revenue Estimate is $107.43M (-6.1% Y/Y).Over the last 1 year, NVRO has beaten EPS estimates 50% of the time and h...
Nevro to Present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference Nevro to Present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference Thursday, February 25, 2021, at 1:30 pm Eastern Time / 10:30 am Pacific Time ...
Nevro to Present at 10th Annual SVB Leerink Global Healthcare Conference Friday, February 26, 2021, at 10:40 am Eastern Time / 7:40 am Pacific Time PR Newswire REDWOOD CITY, Calif. , Feb. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global m...
Nevro to Report Fourth Quarter and Full-Year 2020 Financial Results Company to Host Conference Call on Wednesday, February 24, 2021, at 1:30 pm PT / 4:30 pm ET PR Newswire REDWOOD CITY, Calif. , Jan. 27, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO)...
Nevro Corp. (NVRO) announced results from data presentations at 2021 North American Neuromodulation Society (“NANS”) supporting the use of HF10® therapy for patients with chronic pain.The presentations also included the results of Painful Diabetic Neuropathy (...
Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro's HF10® Therapy PDN Randomized Trial Demonstrates Significantly Improved and Sustained Outcomes NSRBP Randomized Trial Demonstrates Supe...
Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting PR Newswire REDWOOD CITY, Calif. , Jan. 14, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providi...
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 Revenue Fourth Quarter 2020 Revenue of Approximately $109.7 Million Full-Year 2020 Revenue of Approximately $362.0 Million Company to Present at J.P. Morgan Healthcare Conference on Tuesday, January...
Nevro (NVRO) fell 3.1% after Scorpion Capital mentioned the company cautiously, citing its valuation at 15x sales as well as other issues.Scorpion Capital is run by Kir Kahlon, who was formerly with Seligman Investments, where AxoGen was recommended as a short and Fanhua was also re...
Nevro (NVRO) has submitted a pre-market approval supplement to the FDA seeking approval of its Senza System for the treatment of chronic pain associated with Painful Diabetic Neuropathy ((PDN)). This submission, assuming a six-month review cycle, would position the company to achieve FDA appr...
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...